This was an open-label study in 51 people suppressed on ART, who had metabolic-associated steatotic liver disease (MASLD, previously called NAFLD [non-alcoholic])
People included in the analysis all had records of obesity and did not have diabetes, which itself can cause gastroparesis
For glycemic control in patients with type 2 diabetes, less frequent dosing may lead to deterioration in blood glucose management
SURMOUNT-1 (N=2,539) demonstrated 20.9% mean body weight reduction at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo
other exponents are indicator variables assigned the value 1 for the specific covariate values and 0 otherwise, CL ref , Q ref , V c ,ref, V p ,ref, F ref and k a , ref are the parameter values for the reference subject profile T fasting post-dose fasting time (min)
Refrigerate at 36 to 46 degrees Fahrenheit (2 to 8 Celsius) on an interior shelf, not in the door